INT6/EIF3E interacts with ATM and is required for proper execution of the DNA damage response in human cells

Cancer Research

Volumn 72, Issue 8, 2012, Pages 2006-2016

  Morris, Christelle ^a   Tomimatsu, Nozomi ^b   Richard, Derek J ^c   Cluet, David ^a   Burma, Sandeep ^b   Khanna, Kum Kum ^c   Jalinot, Pierre ^a  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; BRCA1 PROTEIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; INITIATION FACTOR 3; INITIATION FACTOR 3E; UNCLASSIFIED DRUG; ZINOSTATIN;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CELL RESPONSE; CELL SURVIVAL; CELLULAR, SUBCELLULAR AND MOLECULAR BIOLOGICAL PHENOMENA AND FUNCTIONS; DNA DAMAGE; ENZYME PHOSPHORYLATION; G2 PHASE CELL CYCLE CHECKPOINT; GAMMA IRRADIATION; GENE; GENE SILENCING; HUMAN; HUMAN CELL; INTEGRATION SITE 6 GENE; M PHASE CELL CYCLE CHECKPOINT; PRIORITY JOURNAL; PROTEIN INTERACTION; RNA INTERFERENCE; UBIQUITINATION;

BRCA1 PROTEIN; CELL CYCLE CHECKPOINTS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; DNA DAMAGE; DNA-BINDING PROTEINS; EUKARYOTIC INITIATION FACTOR-3; FLUORESCENT ANTIBODY TECHNIQUE; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MICROSCOPY, CONFOCAL; PROTEIN-SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS;

EID: 84860166150     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-2562     Document Type: Article

References (48)

1. Lukas J, Lukas C, Bartek J. Mammalian cell cycle checkpoints: signalling pathways and their organization in space and time. DNA Repair (Amst) 2004;3:997-1007. (Pubitemid 38997942)
2. Ciccia A, Elledge SJ. TheDNAdamage response: making it safe to play with knives. Mol Cell 2010;40:179-204.
3. Lavin M. Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol 2008;9:759-69.
4. Berkovich E, Monnat RJ, Kastan M. Roles of ATM and NBS1 in chromatin structure modulation and DNA double-strand break repair. Nat Cell Biol 2007;9:683-90. (Pubitemid 47214731)
5. You Z, Bailis JM, Johnson SA, Dilworth SM, Hunter T. Rapid activation of ATM on DNA flanking double-strand breaks. Nat Cell Biol 2007;9:1311-8. (Pubitemid 350042363)
6. Huen M, Grant R, Manke I, Minn K, Yu X, Yaffe M, et al. RNF8 transduces the DNA-damage signal via histone ubiquitylation and checkpoint protein assembly. Cell 2007;131:901-14. (Pubitemid 350138083)
7. Kolas N, Chapman J, Nakada S, Ylanko J, Chahwan R, Sweeney F, et al. Orchestration of the DNA-damage response by the RNF8 ubiquitin ligase. Science 2007;318:1637-40. (Pubitemid 350233664)
8. Mailand N, Bekker-Jensen S, Faustrup H, Melander F, Bartek J, Lukas C, et al. RNF8 ubiquitylates histones at DNA double-strand breaks and promotes assembly of repair proteins. Cell 2007;131:887-900. (Pubitemid 350138084)
9. Nathanson K, Wooster R, Weber B, Nathanson K. Breast cancer genetics: what we know and what we need. Nat Med 2001;7:552-6. (Pubitemid 32448321)
10. Swift M, Morrell D, Massey R, Chase C. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 1991;325:1831-6.
11. Thompson D, Duedal S, Kirner J, McGuffog L, Last J, Reiman A, et al. Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst 2005;97:813-22. (Pubitemid 40909124)
12. Renwick A, Thompson D, Seal S, Kelly P, Chagtai T, Ahmed M, et al. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 2006;38:873-5. (Pubitemid 44141653)
13. Chenevix-Trench G, Spurdle AB, Gatei M, Kelly H, Marsh A, Chen X, et al. Dominant negative ATM mutations in breast cancer families. J Natl Cancer Inst 2002;94:205-15. (Pubitemid 34162754)
14. Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, et al. Low-penetrance susceptibility to breast cancer due to CHEK2(+)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002;31:55-9.
15. Walsh T, Casadei S, Coats K, Swisher E, Stray S, Higgins J, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 2006;295:1379-88.
16. Górski B, Debniak T, Masojć B, Mierzejewski M, Medrek K, Cybulski C, et al. Germline 657del5 mutation in the NBS1 gene in breast cancer patients. Int J Cancer 2003;106:379-81. (Pubitemid 36870400)
17. Heikkinen K, Rapakko K, Karppinen S, Erkko H, Knuutila S, Lundán T, et al. RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability. Carcinogenesis 2006;27:1593-9. (Pubitemid 44288048)
18. Bartkova J, Tommiska J, Oplustilova L, Aaltonen K, Tamminen A, Heikkinen T, et al. Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene. Mol Oncol 2008;2:296-316.
19. Asano K, Merrick W, Hershey J. The translation initiation factor eIF3-p48 subunit is encoded by int-6, a site of frequent integration by the mouse mammary tumor virus genome. J Biol Chem 1997;272:23477-80. (Pubitemid 27410912)
20. Marchetti A, Buttitta F, Miyazaki S, Gallahan D, Smith G, Callahan R. Int-6, a highly conserved, widely expressed gene, is mutated by mouse mammary tumor virus in mammary preneoplasia. J Virol 1995;69:1932-8.
21. Rasmussen S, Kordon E, Callahan R, Smith G. Evidence for the transforming activity of a truncated Int6 gene, in vitro. Oncogene 2001;20:5291-301. (Pubitemid 32844061)
22. Mack D, Boulanger C, Callahan R, Smith G. Expression of truncated Int6/eIF3e in mammary alveolar epithelium leads to persistent hyperplasia and tumorigenesis. Breast Cancer Res 2007;9:R42.
23. Marchetti A, Buttitta F, Pellegrini S, Bertacca G, Callahan R. Reduced expression of INT-6/eIF3-p48 in human tumors. Int J Oncol 2001;18:175-9.
24. Umar A, Kang H, Timmermans A, Look M, Meijer-van Gelder M, den Bakker M, et al. Identification of a putative protein profile associated with tamoxifen therapy resistance in breast cancer. Mol Cell Proteomics 2009;8:1278-94.
25. Suo J, Snider SJ, Mills GB, Creighton CJ, Chen AC, Schiff R, et al. Int6 regulates both proteasomal degradation and translation initiation and is critical for proper formation of acini by human mammary epithelium. Oncogene 2011;30:724-36.
26. Morris C, Wittmann J, JackHM, Jalinot P. Human INT6/eIF3e is required for nonsense-mediated mRNA decay. EMBO Rep 2007;8:596-602. (Pubitemid 47214715)
27. Ziv Y, Bar-Shira A, Pecker I, Russell P, Jorgensen T, Tsarfati I, et al. Recombinant ATM protein complements the cellular A-T phenotype. Oncogene 1997;15:159-67. (Pubitemid 27344555)
28. Canman C, Lim D, Cimprich K, Taya Y, Tamai K, Sakaguchi K, et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 1998;281:1677-9. (Pubitemid 28435584)
29. Khanna KK, Keating KE, Kozlov S, Scott S, Gatei M, Hobson K, et al. ATM associates with and phosphorylates p53: mapping the region of interaction. Nat Genet 1998;20:398-400. (Pubitemid 28541643)
30. Tomimatsu N, Mukherjee B, Burma S. Distinct roles of ATR and DNAPKcs in triggering DNA damage responses in ATM-deficient cells. EMBO Rep 2009;10:629-35.
31. Bolderson E, Tomimatsu N, Richard DJ, Boucher D, Kumar R, Pandita TK, et al. Phosphorylation of Exo1 modulates homologous recombination repair of DNA double-strand breaks. Nucleic Acids Res 2010;38:1821-31.
32. Morris-Desbois C, Bochard V, Reynaud C, Jalinot P. Interaction between the Ret finger protein and the int-6 gene product and colocalisation into nuclear bodies. J Cell Sci 1999;112:3331-42. (Pubitemid 29507213)
33. Morris-Desbois C, Rety S, Ferro M, Garin J, Jalinot P. The human protein HSPC021 interacts with Int-6 and is associated with eukaryotic translation initiation factor 3. J Biol Chem 2001;276:45988-95.
34. So S, Davis AJ, Chen DJ. Autophosphorylation at serine 1981 stabilizes ATM at DNA damage sites. J Cell Biol 2009;187:977-90.
35. Schwanhäusser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, et al. Global quantification of mammalian gene expression control. Nature 2011;473:337-42.
36. Watkins SJ, Norbury CJ. Cell cycle-related variation in subcellular localization of eIF3e/INT6 in human fibroblasts. Cell Prolif 2004;37:149-60. (Pubitemid 38429326)
37. Grzmil M, Rzymski T, Milani M, Harris AL, Capper RG, Saunders NJ, et al. An oncogenic role of eIF3e/INT6 in human breast cancer. Oncogene 2010;29:4080-9.
38. Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, Dunaway DL, et al. Direct multiplexed measurement of gene expression with colorcoded probe pairs. Nat Biotechnol 2008;26:317-25. (Pubitemid 351355126)
39. Beaume M, Hernandez D, Docquier M, Delucinge-Vivier C, Descombes P, François P. Orientation and expression of methicillin-resistant Staphylococcus aureus small RNAs by direct multiplexed measurements using the nCounter of NanoString technology. J Microbiol Methods 2011;84:327-34.
40. Hoareau Alves K, Bochard V, Réty S, Jalinot P. Association of the mammalian proto-oncoprotein Int-6 with the three protein complexes eIF3, COP9 signalosome and 26S proteasome. FEBS Lett 2002;527:15-21. (Pubitemid 35253831)
41. Pick E, Hofmann K, Glickman M. PCI complexes: beyond the proteasome, CSN, and eIF3 Troika. Mol Cell 2009;35:260-4.
42. Matsuoka S, Ballif BA, Smogorzewska A,McDonald ER, Hurov KE, Luo J, et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 2007;316:1160-6. (Pubitemid 46877472)
43. Mu JJ, Wang Y, Luo H, Leng M, Zhang J, Yang T, et al. A proteomic analysis of ataxia telangiectasia-mutated (ATM)/ATM-Rad3-related (ATR) substrates identifies the ubiquitin-proteasome system as a regulator for DNA damage checkpoints. J Biol Chem 2007;282:17330-4. (Pubitemid 47100266)
44. Bensimon A, Schmidt A, Ziv Y, Elkon R, Wang SY, Chen DJ, et al. ATM-dependent and -independent dynamics of the nuclear phosphoproteome after DNA damage. Sci Signal 2010;3:rs3.
45. Krogan NJ, Lam MH, Fillingham J, Keogh MC, Gebbia M, Li J, et al. Proteasome involvement in the repair of DNA double-strand breaks. Mol Cell 2004;16:1027-34. (Pubitemid 40018411)
46. Jacquemont C, Taniguchi T. Proteasome function is required for DNA damage response and fanconi anemia pathway activation. Cancer Res 2007;67:7395-405. (Pubitemid 47206570)
47. Bryant H, Schultz N, Thomas H, Parker K, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature 2005;434:913-7. (Pubitemid 40559005)
48. Farmer H, McCabe N, Lord C, Tutt A, Johnson D, Richardson T, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21. (Pubitemid 40559006)